Oxford Biomedica plc (LON:OXB - Get Free Report)'s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 363.88 ($4.83) and traded as low as GBX 289 ($3.83). Oxford Biomedica shares last traded at GBX 290 ($3.85), with a volume of 142,504 shares trading hands.
Oxford Biomedica Stock Up 1.0%
The firm's fifty day moving average price is GBX 288.63 and its 200-day moving average price is GBX 363.88. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67. The firm has a market capitalization of £311.46 million, a P/E ratio of -2.18 and a beta of 1.09.
Oxford Biomedica (LON:OXB - Get Free Report) last posted its quarterly earnings data on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.55)) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%. As a group, equities research analysts forecast that Oxford Biomedica plc will post -31.0799998 earnings per share for the current year.
About Oxford Biomedica
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
